Applying lessons of immune response to CMV retinitis, AIDS
Modern combination antiretroviral therapy (cART) has transformed the AIDS epidemic and the management of cytomegalovirus (CMV) retinitis.
Seattle-Modern combination antiretroviral therapy (cART) has transformed the AIDS epidemic and the management of cytomegalovirus (CMV) retinitis, said Douglas A. Jabs, MD, MBA.
Speaking at ARVO 2016, Dr. Jabs outlined the pathogenic mechanisms of CMV retinitis, reviewed clinical predictions based on understanding of the pathophysiology, and presented clinical data corroborating those predictions.
SPONSORED: Join us for dinner and diabetes management tips!
The information demonstrated interactions between CMV and HIV and the importance of the immune response in controlling CMV disease, said Dr. Jabs, professor and chairman of ophthalmology, Mount Sinai School of Medicine, New York.
Discussing the variety of mechanisms CMV uses for immune evasion and to establish latent infection, Dr. Jabs said that the virus interferes with class I expression and antigen presentation to CD8+ T cells. It also produces a class I homolog on the surface of infected cells so that it avoids natural killer (NK) cell clearance.
In addition, the virus produces an IL-10 homolog binding to the human IL-10 receptor and downregulates Th1 responses.
Internal server error